Calliditas Therapeutics AB
- Biotech or pharma, therapeutic R&D
Calliditas Therapeutics, an Asahi Kasei company, is a commercial-stage rare disease biopharma with a focus in kidney disease. Calliditas commercialises Nefecon for IgAN, under the brand name TARPEYO, in the United States with partnerships ex-US. Calliditas has a clinical stage Ph2 pipeline asset, setanaxib. This asset is a first-in-class NOX1/4 inhibitor which is being developed in PBC, solid tumors (SCCHN), Alport Syndrome and IPF.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}